Tumor necrosis factor-α augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model

Journal of Immunotherapy

Volumn 23, Issue 4, 2000, Pages 449-455

  Van Ijken, Marc G A ^a   Van Etten, Boudewijn ^a   De Wilt, Johannes H W ^a   Van Tiel, Sandra T ^a   Ten Hagen, Timo L M ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Isolated Hepatic Perfusion; Melphalan; Rats; Sarcoma; Tumor Necrosis Factor

Indexed keywords

MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; IMMUNOPHARMACOLOGY; LIVER PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SOFT TISSUE SARCOMA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; LIVER; LIVER NEOPLASMS; MALE; MELPHALAN; RATS; SARCOMA, EXPERIMENTAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033922618     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200007000-00008     Document Type: Article

References (47)

1. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987;47:2986-9.
2. Selby P, Hobbs S, Viner C, et al. Tumor necrosis factor in man: clinical and biological observations. Br J Cancer 1987;56:803-8.
3. Eggermont AMM, Schraffordt Koops H, Liénard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14: 2653-65.
4. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg 1996;224:756-65.
5. Liénard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High doses of tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
6. Borel Rinkes IHM, De Vries MR, Jonker AM, et al. Isolated hepatic perfusion in the pig with TNF-a with and without melphalan. Br J Cancer 1997;75:1447-53.
7. de Vries MR, Borel Rinkes IHM, Van de Velde CJH, et al. Isolated hepatic perfusion with TNF-α and melphalan: experimental studies in pigs and phase I data from humans. Recent Results in Cancer Research 1998;147:107-19.
8. van IJken MGA, de Bruijn EA, de Boeck G, Ten Hagen TLM, van der Sijp JR, Eggermont AMM. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann Surg 1998;228:763-70.
9. van der Veen AH, Seynhaeve ALB, Breurs J, Nooijen PTGA, Marquet RL, Eggermont AMM. In vivo isolated kidney perfusion with tumour necrosis factor a in tumour-bearing rats. Br J Cancer 1999;79:433-9.
10. Häfstrom LR, Holmberg SB, Naredi PL, et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 1994;3:103-8.
11. Vahrmeijer AL, van der Eb MM, van Dierendonck JH, Kuppen PJ, Van de Velde CJ. Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? Semin Surg Oncol 1998;14:262-8.
12. Marinelli A, van Dierendonck JH, van Brakel GM, et al. Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion. Br J Cancer 1991;64:1069-75.
13. Fraker DL, Alexander HR, Thorn AK. Use of tumor necrosis factor in isolated hepatic perfusion. Circ Shock 1994;44:45-50.
14. Alexander HR, Baartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor (TNF) and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998;16:1479-89.
15. Oldhafer KJ, Lang H, Frerker M, et al. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. Surgery 1998;123:622-31.
16. Lindner P, Fjalling M, Hafstrom L, et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur J Surg Oncol 1999;25:179-85.
17. Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL, Eggermont AMM: Synergistic antitumour effect of recombinant tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 1996;83:551-5.
18. Nooijen PTGA, Manusama ER, Eggermont AMM, et al. Synergistic antitumour effects of TNF-a and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathologic, immunohistochemical and electron microscopic study. Br J Cancer 1996; 74:1908-15.
19. de Wilt JHW, Manusama ER, van Tiel ST, Van IJken MGA, Ten Hagen TLM, Eggermont AMM. Prerequisites for an optimal isolated extremity perfusion with tumour necrosis factor alpha and melphalan. Br J Cancer 1999;80:161-6.
20. Kramer SM, Carver ME. Serum-free in vitro bioassay for the detection of tumor necrosis factor-α. J Immunol Meth 1986;93: 201-6.
21. De Brauw LM, Marinelli A, van de Velde CJH, et al. Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. Cancer Res 1991;51: 1694-1700.
22. Engelberts I, Moller A, Schoen GJ, Van der Linden CJ, Buurman WA. Evaluation of measurement of TNF in plasma by ELISA. Lymphokine and Cytokine Research 1991;10:69-76.
23. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culhane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluoro-deoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-93.
24. Rougier PH, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal cancer; long term results of a prospective randomised trial. J Clin Oncol 1992;10:1112-15.
25. Meta-analysis Group in Cancer (MAGIC): Reappraisal of hepatic artery infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252-8.
26. Ensminger WD, Rosowsky A, Raso V, et al: A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluorodeoxyuridine and 5-fluorouracil. Cancer Res 1978;38(11 Pt 1): 3784-92.
27. Marinelli A, van de Velde CJH, Kuppen PJK, Franken HC, Souverijn JH, Eggermont AMM. A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. Br J Cancer 1990;62:891-6.
28. Aigner KR, Walther H, Tonn JC, et al. Die isolierte Leberperfusion mit 5-Fluorouracil (5-FU) beim Menschen. Chirurg 1982;53: 571-3.
29. Skibba JL, Almagro KA, Condon RE, Petroff RJA. A technique for isolation perfusion of the canine liver with survival. J Surg Res 1983;34:123-32.
30. Van de Velde CJH, Kothuis BJL, Barenbrug HWM, et al. A successful technique of in-vivo isolated liver perfusion in pigs. J Surg Res 1986;41:593-9.
31. Strohmeyer T, Haugeberg G, Lierse W. Vaskularisation von Lebermetastasen: eine korrosionsanatomischen Studie. Acta Anat 1986;126:172-6.
32. Renard N, Liénard D, Lespagnard L, Eggermont, Heimann R, Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rhTNF-a). Int J Cancer 1994;57:656-63.
33. Ruegg C, Yilmaz A, Bieler G, Bamat J, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998;4:408-14.
34. Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC. Dual role of tumor necrosis factor-α in angiogenesis. Am J Pathol 1992; 140:539-44.
35. Renard N, Nooijen PTGA, Schalkwijk L, et al. VWF release and platelet aggregation in human melanoma after perfusion with TNFa. J Pathol 1995;176:279-87.
36. De Wilt JHW, ten Hagen TLM, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AMM. Tumour necrosis factor alpha increases melphalan accumulation in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000-3.
37. Vander Veen AH, DeWilt JWH, Eggermont AMM, van Tiel ST, Seynhaeve AL, ten Hagen TLM. TNF-a augments intratumoral concentrations of doxorubicin in TNF-a-based isolated limb perfusion in rat sarcoma models and enhances anti tumor effects. Br J Cancer 2000;82:973-80.
38. Alexander HR, Brown KC, Bartlett DL, et al. Augmented Capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. Clin Canc Res 1998;4: 2357-62.
39. Kuppen PJK, Jonges LE, Van de Velde CJH, et al. Liver and tumour tissue concentrations of TNF-α in cancer patients treated with TNF-α and melphalan by isolated liver perfusion. Br J Cancer 1997;75:1497-1500.
40. Tran-Thi T-A, Weinhold L, Weistock C, et al. Production of tumor necrosis factor-a, interleukin-1 and interleukin-6 in the perfused rat liver. Eur Cytokine Netw 1993;4:363-70.
41. de Vries MR, Borel Rinkes IHM, et al. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor a (TNFa) and melphalan in patients with colorectal metastases. Eur J Clin Invest 1999;29:553-60.
42. de Vries MR, Borel Rinkes IHM, Rack CE, et al. Isolated hepatic perfusion with TNFa and melphalan: local and systemic effects on secondary cytokine release, coagulation and fibrinolysis. Eur J Surg Res 1995;27(S1):109.
43. Skibba JL, Quebbeman EJ. Tumoricidal effects and patient survival after hyperthermic liver perfusion. Arch Surg 1986;121: 1266-71.
44. Eggermont AMM, van IJken MGA, van Etten B, et al. Isolated hypoxic hepatic perfusion using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology 2000 (In press).
45. de Wilt JHW, Soma GI, ten Hagen TLM, et al. Synergistic anti-tumor effect of TNF-mutant (TNF-SAM2) with melphalan and doxorubicin in isolated limb perfusion in rats. Anticancer Res 2000 (In press).
46. Bianchi M, Bloom O, Raabe T, et al. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med 1996;183:927-36.
47. Kemeny MM, Botchkina GI, Ochani M, Bianchi M, Urmacher C, Tracey KJ. The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy. Proc Natl Acad Sci 1998;95:4561-6.